From the FDA

Publisher： John Wiley & Sons Inc

E-ISSN： 1556-7532|29|3|8-8

ISSN： 1068-5308

Source： THE BROWN UNIVERSITY PSYCHOPHARMACOLOGY UPDATE, Vol.29, Iss.3, 2018-03, pp. : 8-8

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

From the FDA

By  

THE BROWN UNIVERSITY CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY UPDATE, Vol. 17, Iss. 2, 2015-02 ,pp. : 8-8

John Wiley & Sons Inc

Access to resources Recommend Favorite

Cardiovascular and pulmonary adverse events in patients treated with BCR‐ABL inhibitors: Data from the FDA Adverse Event Reporting System

By  

AMERICAN JOURNAL OF HEMATOLOGY, Vol. 90, Iss. 4, 2015-04 ,pp. : E66-E72

John Wiley & Sons Inc

Access to resources Recommend Favorite

New Drugs Accepted by the FDA

By  

JOURNAL OF AMERICAN GERIATRICS SOCIETY, Vol. 12, Iss. 8, 1964-08 ,pp. : 811-811

John Wiley & Sons Inc

Access to resources Recommend Favorite

FDA announces modified and revised REMS

By  

ALCOHOLISM AND DRUG ABUSE WEEKLY, Vol. 27, Iss. 15, 2015-04 ,pp. : 7-7

John Wiley & Sons Inc

Access to resources Recommend Favorite

Ticagrelor FDA Approval Issues Revisited

By  

Cardiology, Vol. 122, Iss. 3, 2012-07 ,pp. : 144-147

Karger

Access to resources Recommend Favorite